Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Latest News

Market cap$50M–$100B
All Over $50MOver $300MOver $2BOver $10B
All Under $1BUnder $10BUnder $100BUnder $500B
SectorsAll
Filter by sector
Wednesday, October 21, 2026· 8051 stock ideas· 218 writers·
21,574 views· 10,023 clicks

Why I sold OB pick for 26 SVM

Silvercorp’s falling Ying grades, prolonged GC suspension, El Domo execution risk and Chaarat funding needs weaken its valuation despite higher silver prices.

SVM $2.1B
The Oak Bloke 6 clicks

From X

@kevin__mak

Kevin Mak on X

I think this is a good analysis and I'm long $QURE, but I want to flag something about this style of argument because it shows up across a lot of stocks. The common version is "the fundamentals are much better than they were x years ago, but the market cap is the same, so it must be underpriced." That doesn't follow. A disconnect like that means one of the two prices was wrong. It could be too cheap now, or it could have been too expensive before. All you actually know is that the market was probably wrong once. (To credit: @ClearPath100 doesn't explicitly say it's underpriced here.) That said, I still think these situations are worth finding. I generally assume the market is more often right than wrong, so a stock that moves with its fundamentals isn't very interesting. The disconnects are where the market might be wrong, and that's what we want. You just have to do the work to figure out which price was the wrong one. For QURE, I think the shorter comparison is more useful than the 5 year one. The stock was $70+ before the FDA denial that took it to $8. It's $48 today at a lower market cap than it was at $70. In between, the path to approval got better, not worse. The BLA is filed, the confirmatory study design is agreed, the timeline to commercialization is shorter, there's a year more of follow up data, and more cash on the balance sheet. Every risk that exists today also existed at $70. The biggest risk that did exist at $70, the FDA refusing the dataset, has already played out and been resolved. So which price was wrong? My guess is a lot of sharp people owned this at $70+, dumped it on the news, and never came back. I think they were right to sell back then. But if you were right to own it at $75 with more risks and a longer timeline, you should want to own it even more at $48 with fewer risks and a shorter one. Not buying it back isn't consistent with their own original view. I think the reason is simple. Losing 75% on a stock stings, and it's a lot easier to stay away than to admit the same thesis is back on the table at a better price. That's part of why we own it here. Disclosure: Creek Drive and its affiliated funds holds a long position in QURE. Views expressed are current opinions for informational educational only, subject to change and are not investment advice or a recommendation to buy or sell any security. Investing involves the risk of loss and past performance is not indicative of future performance. See the disclosures link in my bio for more important information.

Investor Letters

All letters

Free Recaps of the best new stock ideas, delivered every morning.

Read past recaps

Carecloud News

CareCloud may attract a private-equity buyer after its Q3 call, with acquiring enough shares the main obstacle to a take-private deal.

CCLD $79M
Calvin Blissett 4 clicks

Heico Corporation

HEICO sells FAA-approved aircraft replacement parts at 30% to 50% discounts to OEMs, gaining customers as restrictive aftermarket contracts…

HEI $43B
D Invests 6 clicks

Copper Fox Metals: Research Flash

Copper Fox’s C$9.1 million Schaft Creek program advances metallurgical, tailings, water and road studies toward a pre-feasibility study,…

TECK $31B
Atrium Research - Equity Research 4 clicks
CHGG · long

Chegg Inc

Chegg is framed as a binary long with 500% upside against 20% downside.

CHGG $78M
Value Investors Club 2 clicks

AppLovin Deep Dive

AppLovin rebuilt its ad model with AXON 2.0, lifting LTM revenue to about $7 billion and margins to 77% as Unity competition threatens ad…

APP $92BU $19B
Speedwell Memos 63 clicks

LXS.DE: a 2028 sale it can force

Lanxess can force Advent to buy at least half its Envalior stake in April 2028, potentially raising about €745 million to reduce net debt.

LPTH $525M
Trade Ideas Flow 18 clicks

Build-A-Bear: A Narrower Path

Build-A-Bear's push into prestuffed toys and broader retail distribution tests brand stretchability, but recent results warrant caution.

BBW $303M
TSOH Investment Research 16 clicks

Have a source we’re missing? Send your pick

Recent recaps

Latest recap

Monday, October 19 52 stock ideas
  • 40 Stock Pitches (12th-18th October) 🖨️ Capital Employed
  • The Monday Morning Briefing: Meta, Tesla, Netflix, P&G on Deck Latticework by MOI Global
Read the recap

All recaps

Publications we follow

Every publication on this site, hand-picked.

128 publications

Newsletters 108

YouTube 4

Blogs 15

Seeking Alpha 52 of 244

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

90 accounts
Nominate an account

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.

Anything we’re missing?

Send us a pick